Literature DB >> 2292203

In vitro susceptibility testing of Candida isolates from clinical specimens to four antifungal agents.

M Ohkawa1, S Tokunaga, M Takashima, T Nishikawa, H Hisazumi, S Fujita, R W Wheat.   

Abstract

A total of 231 isolates of Candida species including 163 of Candida albicans (132 of serotype A and 31 of serotype B), 42 of Candida tropicalis, 17 of Candida glabrata, 7 of Candida parapsilosis and 2 of Candida krusei were collected from clinical specimens in two medical centers, one in Japan and the other in the United States. The in vitro antifungal activities of amphotericin B, 5-fluorocytosine, miconazole and fluconazole were evaluated for the above isolates by means of a photo-read broth microdilution method for determination of the 30% inhibitory concentration (IC30). The results showed that IC30 values of fluconazole were generally great compared with those of the other drugs, regardless of Candida species. The isolates of C. albicans serotype B showed a significantly lessened susceptibility to 5-fluorocytosine compared with those of serotype A (p less than 0.01). This method has the advantage of objective measurement, thus minimizing observer variability as compared with the agar dilution test.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2292203     DOI: 10.1159/000238795

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  3 in total

1.  Endogenous reactive oxygen species is an important mediator of miconazole antifungal effect.

Authors:  Daisuke Kobayashi; Kei Kondo; Nobuyuki Uehara; Seiko Otokozawa; Naoki Tsuji; Atsuhito Yagihashi; Naoki Watanabe
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

2.  Experimental hematogenous candidiasis caused by Candida krusei and Candida albicans: species differences in pathogenicity.

Authors:  E Anaissie; R Hachem; C K-Tin-U; L C Stephens; G P Bodey
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

Review 3.  Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.

Authors:  K L Goa; L B Barradell
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.